Revvity (NYSE: RVTY) surged past fourth-quarter expectations and issued an upbeat 2026 outlook, driven by robust demand in its diagnostics division. The medical equipment maker's performance highlights a sector-wide resilience despite ongoing softness in academic research funding.
While stocks priced between $10 and $50 can appear to offer an attractive balance of accessibility and maturity, their low price tags can sometimes mask underlying vulnerabilities. We examine three such companies where caution may be prudent.
Danaher Corporation announces a strategic investment in Automata, aiming to integrate AI-ready automation systems with its extensive portfolio of instruments and reagents. The move signals a push to deliver comprehensive, data-driven lab solutions as the life sciences sector increasingly prioritizes efficiency and scalability.
Eli Lilly announces a massive new manufacturing facility in Pennsylvania, part of a strategic pivot by major drugmakers to onshore production amid trade tensions and soaring demand for weight-loss drugs.
Chinese President Xi Jinping and Uruguay's President Yamandú Orsi called for enhanced cooperation to foster an "equal and orderly multipolar world" during a meeting in Beijing. The visit underscores Uruguay's strategic balancing act and China's sustained diplomatic outreach to South America amid global tensions.
Lemonade's stock soared in January, propelled by the launch of a novel, usage-based insurance plan for Tesla vehicles that slashes premiums when Full Self-Driving is engaged, signaling a strategic pivot towards data-driven, autonomous future.
For aspiring homeowners, where to park down payment savings is a critical calculation. With interest rates in flux, the choice between accessible high-yield accounts and locked-in CDs can significantly impact your timeline and final sum.
Nomura Holdings announces a significant share buyback program while tightening risk controls at its digital asset unit, Laser Digital. The move signals a dual focus on immediate capital returns and long-term, regulated growth in the crypto space, as the financial giant navigates a volatile market.
Arcellx shares have delivered stellar multi-year gains, prompting investors to question if the rally still has room to run. A deep dive into valuation metrics reveals a complex picture, with discounted cash flow models pointing to significant upside while price-to-book ratios suggest a more cautious stance.
Stanley Black & Decker announces key leadership changes, appointing a new General Counsel and adding fresh expertise to its board. The moves signal a deeper focus on governance and operational oversight as the company navigates its financial turnaround.
OpenText's appointment of former IBM Americas President Ayman Antoun as its new CEO, effective April 2026, has been met with a sharp sell-off. While the move brings deep cloud and AI expertise, investors appear wary of the leadership transition and strategic pivot amid ongoing portfolio restructuring and debt concerns.
Vertiv's launch of its 'Next Predict' AI service aims to transform data center maintenance. While it strengthens the company's AI infrastructure narrative, investors are weighing rich valuations against execution risks in a maturing growth cycle.
Nurix Therapeutics, a clinical-stage biopharma company, is gaining attention for its novel protein degradation platform. With strong early data for its lead drug, key regulatory designations, and strategic partnerships with industry giants, the company is positioning itself to address unmet needs in multi-billion dollar oncology markets.
Twist Bioscience's proprietary silicon-based DNA manufacturing platform is driving double-digit revenue growth and margin expansion, positioning the synthetic biology tools provider on a clear path to adjusted EBITDA breakeven by fiscal 2026.
Prestige Consumer Healthcare Inc. (PBH) is drawing investor attention following its $662.5 million acquisition of Stampede Culinary Partners. Analysts see the deal as a catalyst for growth, potentially enhancing earnings and expanding the company's footprint in North America's specialty food sector.
Elon Musk's SpaceX is set to acquire his artificial intelligence startup xAI in a landmark share exchange, with investors offered 0.1433 SpaceX shares for each xAI share, according to a source familiar with the transaction. The deal underscores Musk's strategy of consolidating his tech empire amid fierce AI competition.
Facing persistently weak natural gas prices, APA Corporation announces significant production cuts across its U.S. operations while reaffirming its commitment to a multi-billion dollar share repurchase program, signaling a strategic pivot towards capital discipline over volume growth.
Bio-Techne (TECH) gains market attention with the launch of its Cultrex Synthetic Hydrogel, a key innovation for 3D cell research. While the product debut coincides with recent share price strength, longer-term returns tell a more complex story for investors.
Johnson & Johnson's oncology portfolio gains momentum with new clinical data for prostate cancer drug Erleada and a broader FDA label for multiple myeloma therapy Darzalex Faspro, reinforcing its competitive stance in key cancer markets.
The swearing-in of Rep. Christian Menefee (D-Texas) on Monday tightens the House margin to 218-214, leaving Speaker Mike Johnson with virtually no room for error on key votes, starting with this week's critical government funding bill.
